Novel B cell therapeutic targets in transplantation and immune-mediated glomerular diseases

Clinical Journal of the American Society of Nephrology

Volumn 5, Issue 1, 2010, Pages 142-151

  Vincenti, Flavio ^a   Cohen, Scott D ^a   Appel, Gerald ^a  

^a NewYork Presbyterian Hospital   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABATACEPT; ABETIMUS; ATACICEPT; BELIMUMAB; CYCLOPHOSPHAMIDE; EPRATUZUMAB; IMMUNOSUPPRESSIVE AGENT; METHYLPREDNISOLONE; OCRELIZUMAB; RITUXIMAB;

B LYMPHOCYTE; CELL DIFFERENTIATION; DRUG MECHANISM; GLOMERULOPATHY; HUMAN; IMMUNE RESPONSE; KIDNEY DISEASE; KIDNEY TRANSPLANTATION; PLASMA CELL; REVIEW;

AUTOIMMUNE DISEASES; B-LYMPHOCYTES; HUMANS; KIDNEY DISEASES; KIDNEY GLOMERULUS; KIDNEY TRANSPLANTATION;

EID: 75749097369     PISSN: 15559041     EISSN: 1555905X     Source Type: Journal    
DOI: 10.2215/CJN.04580709     Document Type: Review

References (75)

1. Zarkhin V, Li L, Sarwal M: "To B or not to B?" B-cells and graft rejection. Transplantation 85: 1705-1714, 2008
2. Lefaucheur C, Suberbielle-Boissel C, Hill GS, Nochy D, Andrade J, Antoine C, Gautreau C, Charron D, Glotz D: Clinical relevance of preformed HLA donor-specific antibodies in kidney transplantation. Am J Transplant 8: 324-331, 2008
3. Racusen LC, Haas M: Antibody-mediated rejection in renal allografts: Lessons from pathology. Clin J Am Soc Nephrol 1: 415-420, 2006
4. Pescovitz MD: B cells: A rational target in alloantibody-mediated solid organ transplantation rejection. Clin Transplant 10: 48-54, 2005
5. Pescovitz MD: Rituximab, an anti-CD20 monoclonal antibody: History and mechanism of action. Am J Transplant 6: 859-866, 2006
6. Vincenti F, Kirk AD: What's next in the pipeline. Am J Transplant 8: 1972-1981, 2008
7. Schneider P: The role of APRIL and BAFF in lymphocyte activation. Curr Opin Immunol 17: 282-289
8. Dall'Era M, Chakravarty E, Wallace D, Genovese M, Weisman M, Kavanaugh A, Kalunian K, Dhar P, Vincent E, Pena-Rossi C, Wofsy D: Reduced B lymphocyte and immunoglobulin levels after atacicept treatment in patients with systemic lupus erythematosus. Arthritis Rheum 56: 4142-4150, 2007
9. Sayegh MH, Turka LA: The role of T-cell costimulatory activation pathways in transplant rejection. N Engl J Med 228: 1813-1821, 1998
10. Vincenti F: Costimulation blockade in autoimmunity and transplantation. J Allergy Clin Immunol 121: 299-306, 2008
11. Vincenti F, Larsen C, Durrbach A, Wekerle T, Nashan B, Blancho G, Lang P, Grinyo J, Halloran PF, Solez K, Hagerty D, Levy E, Zhou W, Natarajan K, Charpentier B, Belatacept Study Group: Costimulation blockade with belatacept in renal transplantation. N Engl J Med 353: 770-781, 2005
12. Kalunian KC, Davis JC Jr, Merrill JT, Totoritis MC, Wofsy D, IDEC-131 Lupus Study Group: Treatment of systemic lupus erythematosus by inhibition of T cell costimulation with anti-CD154: A randomized, double-blind, placebo-controlled trial. Arthritis Rheum 46: 3251-3258, 2002
13. Boumpas DT, Furie R, Manzi S, Illei GG, Wallace DJ, Balow JE, Vaishnaw A, BG9588 Lupus Nephritis Trial Group: A short course of BG9588 (anti-CD40 ligand antibody) improves serologic activity and decreases hematuria in patients with proliferative lupus glomerulonephritis. Arthritis Rheum 48: 719-727, 2003
14. Strand V, Aranow C, Cardiel MH, Alarcón-Segovia D, Furie R, Sherrer Y, Tumlin J, Wallace DJ, Crawford B, LJP 394 Investigator Consortium: Improvement in health-related quality of life in systemic lupus erythematosus patients enrolled in a randomized clinical trial comparing LJP 394 treatment with placebo. Lupus 12: 677-686, 2003
15. Perry DK, Burns JM, Pollinger HS, Amiot BP, Gloor JM, Gores GJ, Stegall MD: Proteasome inhibition causes apoptosis of normal human plasma cells preventing alloant-ibody production. Am J Transplant 9: 201-209, 2009
16. Everly MJ, Everly JJ, Susskind B, Brailey P, Arend LJ, Alloway RR, Roy-Chaudhury P, Govil A, Mogilishetty G, Rike AH, Cardi M, Wadih G, Tevar A, Woodle ES: Bortezomib provides effective therapy for antibody- and cell-mediated acute rejection. Transplantation 86: 1754-1761, 2008
17. Vo AA, Lukovsky M, Toyoda M, Wang J, Reinsmoen NL, Lai CH, Peng A, Villicana R, Jordan SC: Rituximab and intravenous immune globulin for desensitization during renal transplantation. N Engl J Med 359: 242-291, 2008
18. Stegall MD, Gloor J, Winters JL, Moore SB, Degoey S: A comparison of plasmapheresis versus high-dose IVIG desensitization in renal allograft recipients with high levels of donor specific antibody. Am J Transplant 6: 348-351, 2006
19. Jordan S, Yoyoda M, Vo AA: Intravenous immunoglobulin a natural regulator of immunity and inflammation. Transplantation 88: 1-6, 2009
20. Jordan SC, Tyan D, Stablein D, McIntosh M, Rose S, Vo A, Toyoda M, Davis C, Shapiro R, Adey D, Milliner D, Graff R, Steiner R, Ciancio G, Sahney S, Light J: Evaluation of intravenous immunoglobulin as an agent to lower allosensitization and improve transplantation in highly sensitized adult patients with end-stage renal disease: Report of the NIH IGO2 trial. J Am Soc Nephrol 15: 3256-3262, 2004
21. Lefaucheur C, Nochy D, Andrade J, Verine J, Gautreau C, Charron D, Hill GS, Glotz D, Suberbielle-Boissel C: Comparison of combination plasmapheresis/IVIg/anti-CD20 versus high-dose IVIg in the treatment of antibody-mediated rejection. Am J Transplantation 9: 1099-1107, 2009
22. Browning JL: B cells move to centre stage: Novel opportunities for autoimmune disease treatment. Nat Rev Drug Discov 5: 564-576, 2006
23. Lipsky PE: Systemic lupus erythematosus: An autoimmune disease of B cell hyperactivity. Nat Immunol 2: 764-766, 2001
24. Waldman M, Madaio MP: Pathogenic autoantibodies in lupus nephritis. Lupus 14: 19-24, 2005
25. Jayne D. Role of rituximab therapy in glomerulonephritis. J Am Soc Nephrol September 17, 2008 [epub ahead of print]
26. Bhat P, Radhakrishnan JB: lymphocytes and lupus nephritis: New insights into pathogenesis and targeted therapies. Kidney Int 73: 261-268, 2008
27. McKay J, Merrill JT, Wallace DJ, Furie RL, Stohl W, Latinis K, Wellborne F, Wolfe S, Angelly T, Chen A, Pineda L, Hough D: Efficacy and Safety of Rituximab in Patients with Moderately to Severely Active Systemic Lupus Erythematosus (SLE): Results from the Randomized, Double-Blind Phase II/III Study EXPLORER. Presented at the 72nd Annual Scientific Meeting of the American College of Rheumatology; October 24-29, 2008; San Francisco, CA
28. Rovin BH, Appel G, Furie R, Kamen D, Fervenza FC, Spindler A, Maciuca R, Garg J: Efficacy and safety of rituximab in subjects with active proliferative lupus nephritis: Results from the randomized, double-blind phase III Lunar study [Abstract]. J Am Soc Nephrol 20: 406A, 2009
29. Sfikakis PP, Boletis JN, Lionaki S, Vigklis V, Fragiadaki KG, Iniotaki A, Moutsopoulos HM: Remission of proliferative lupus nephritis following B cell depletion therapy is preceded by down-regulation of the T cell costimulatory molecule CD40 ligand. Arthritis Rheum 52: 501-513, 2005
30. Lindholm C, Borjesson-Asp K, Zendjanchi K, Sundqvist AC, Tarkowski A, Bokarewa M: Longterm clinical and immunological effects of anti-CD20 treatment in patients with refractory systemic lupus erythematosus. J Rheumatol 35: 826-833, 2008
31. Vigna-Perez M, Hernández-Castro B, Paredes-Saharopulos O, Portales-Pérez D, Baranda L, Abud-Mendoza C, Gonzá-lez-Amaro R: Clinical and immunological effects of rituximab in patients with lupus nephritis refractory to conventional therapy: A pilot study. Arthritis Res Ther 8: R83, 2006
32. Eisenberg R, Looney RJ: The therapeutic potential of anti-CD20 "what do B-cells do?" Clin Immunol 117: 207-213, 2005
33. A Study to Evaluate Ocrelizumab in Patients With Nephritis Due to Systemic Lupus Erythematosus (BELONG). Available at: http://clinicaltrials.gov/ ct2/show/NCT00626197. Accessed May 4, 2009
34. Dorner T, Kaufmann J, Wegener WA, Teoh N, Goldenberg DM, Burmester GR: Initial clinical trial of epratuzumab (humanized anti-CD22 antibody) for immunotherapy of systemic lupus erythematosus. Arthritis Res Ther 8: R74, 2006
35. Finck BK, Linsley PS, Wofsy D: Treatment of murine lupus with CTLA4Ig. Science 265: 1225-1227, 1994
36. Stohl W: Systemic lupus erythematosus: A BLySful, yet BAFFling, disorder. Arthritis Res Ther 5: 136-138, 2003
37. Furie R, Stohl W, Ginzler EM, Becker M, Mishra N, Chatham W, Merrill JT, Weinstein A, McCune WJ, Zhong J, Cai W, Freimuth W; Belimumab Study Group: Biologic activity and safety of belimumab, a neutralizing anti-Blymphocyte stimulator (BLyS) monoclonal antibody: a phase I trial in patients with systemic lupus erythematosis. Arthritis Res Ther 10(5): R109, 2008
38. Jayne DR, Gaskin G, Rasmussen N, Abramowicz D, Ferrario F, Guillevin L, Mirapeix E, Savage CO, Sinico RA, Stegeman CA, Westman KW, van der Woude FJ, de Lind van Wijngaarden RA, Pusey CD; European Vasculitis Study Group: Randomized trial of plasma exchange or high-dosage methylprednisolone as adjunctive therapy for severe renal vasculitis. J Am Soc Nephrol 18: 2180-2188, 2007
39. Xiao H, Heeringa P, Hu P, Liu Z, Zhao M, Aratani Y, Maeda N, Falk RJ, Jennette JC: Antineutrophil cytoplasmic autoantibodies specific for myeloperoxidase cause glomerulonephritis and vasculitis in mice. J Clin Invest 110: 955-963, 2002
40. Keogh KA, Wylam ME, Stone JH, Specks U: Induction of remission by B lymphocyte depletion in eleven patients with refractory antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum 52: 262-268, 2005
41. Keogh KA, Ytterberg SR, Fervenza FC, Carlson KA, Schroeder DR, Specks U: Rituximab for refractory Wegener's granulomatosis. Am J Respir Crit Care Med 173: 180-187, 2006
42. Stasi R, Stipa E, Del Poeta GD, Amadori S, Newland AC, Provan D: Long-term observation of patients with antineutrophil cytoplasmic antibody-associated vasculitis treated with rituximab. Rheumatology 45: 1432-1436, 2006
43. J Jones R, Walsh M, Jayne D: Randomised Trial of Rituximab versus Cyclosphosphamide as Induction Therapy for ANCA Associated Renal Vasculitis: RITUXVAS [Abstract]. J Am Soc Nephrol 19: 61A, 2008
44. Arzoo K, Sadeghi S, Liebman HA: Treatment of refractory antibody mediated autoimmune disorders with an anti-CD20 monoclonal antibody (rituximab). Ann Rheum Dis 61: 922-924, 2002
45. Wechsler E, Yang T, Jordan SC, Vo A, Nast CC: Antiglomerular basement membrane disease in an HIV-infected patient. Nat Clin Pract Nephrol 4: 167-171, 2008
46. Ruggenenti P, Churchiu C, Abbate M, Perna A, Cravedi P, Bontempelli M, Remuzzi G: Rituximab for idiopathic membranous nephropathy: Who can benefit? Clin J Am Soc Nephrol 1: 738-748, 2006
47. Ruggenenti P, Chiurchiu C, Brusegan V, Abbate M, Perna A, Filippi C, Remuzzi G: Rituximab in idiopathic membranous nephropathy: A one year prospective study. J Am Soc Nephrol 14: 1851-1857, 2003
48. Fervenza FC, Cosio FG, Erickson SB, Specks U, Herzenberg AM, Dillon JJ, Leung N, Cohen IM, Wochos DN, Bergstralh E, Hladunewich M, Cattran DC: Rituximab treatment of idiopathic membranous nephropathy. Kidney Int 73: 117-125, 2008
49. Bomback AS, Derebail VK, McGregor JG, Kshirsagar AV, Falk RJ, Nachman PH: Rituximab therapy for membranous nephropathy: A systematic review. Clin J Am Soc Nephrol 4: 734-744, 2009
50. Bayrakci US, Baskin E, Sakalli H, Karakayali H, Haberal M: Rituximab for post-transplant recurrences of FSGS. Pediatr Transplant 13: 240-243, 2009
51. Kamar N, Faguer S, Esposito L, Guitard J, Nogier MB, Durand D, Rostaing L: Treatment of focal segmental glomerular sclerosis with rituximab: 2 case reports. Clin Nephrol 67: 250-254, 2007
52. Hristea D, Hadaya K, Marangon, Buhler L, Villard J, Morel P, Martin PY: Successful treatment of recurrent focal segmental glomerulosclerosis after kidney transplantation by plasmapheresis and rituximab. Transpl Int 20: 102-105, 2007
53. Gossmann J, Scheuermann EH, Porubsky S, Kachel HG, Geiger H, Hauser IA: Abrogation of nephrotic proteinuria by rituximab treatment in a renal transplant patient with relapsed focal segmental glomerulosclerosis. Transpl Int 20: 558-562, 2007
54. Yabu JM, Ho B, Scandling JD, Vincenti F: Rituximab failed to improve nephrotic syndrome in renal transplant patients with recurrent focal segmental glomerulosclerosis. Am J Transplant 8: 222-227, 2008
55. Hyla-Klekot L, Grenda R, Pulcer B: No effect of rituximab in pediatric case of severe nephrotic syndrome and focal segmental glomerulosclerosis accompanied by renal insufficiency. Pol Merkur Lekarski 25: 519-522, 2008
56. Suri M, Tran K, Sharma AP, Filler G, Grimmer J: Remission of steroid-resistant nephrotic syndrome due to focal and segmental glomerulosclerosis using rituximab. Int Urol Nephrol 40: 807-810, 2008
57. Peters HP, van de Kar NJ, Wetzels JM: Rituximab in minimal change nephropathy and focal segmental glomerulosclerosis: Report of four cases and review of the literature. Neth J Med 66: 408-415, 2008
58. Kemper MJ, Dittrich K, Billing H, Pape L, Cortina G, Habbig S, Phol M, Ehrich JH, Zimmerhackl LB, Toenshoff B, Doetsch J, Mueller-Wiefel DE: Rituximab (RTX) for refractory steroid sensitive nephrotic syndrome (SSNS): Registry of German Pediatric Nephrology Association (GPN). J Am Soc Nephrol 19: 558A, 2008
59. Bruchfeld A, Benedek S: Rituximab for multilapsing and steroid-dependent minimal-change nephropathy (MCN) [Abstract]. J Am Soc Nephrol 19: 558A, 2008
60. Kamei K, Nozu K, Ito S, Fujinaga S, Iijima K: Treatment of refractory steroid-dependent nephrotic syndrome with a single dose of rituximab, a multicenter prospective study [Abstract]. J Am Soc Nephrol 19: 558A, 2008
61. Yuling H, Ruijing X, Xiang J, Yanping J, Lang C, Li L, Dingping Y, Xinti T, Jingyi L, Zhiqing T, Yongyi B, Bing X, Xinxing W, Youxin J, Fox DA, Lundy SK, Guohua D, Jinquan T: CD19+CD5+ B cells in primary IgA nephropathy. J Am Soc Nephrol 19: 2130-2139, 2008
62. Visentini M, Granata M, Veneziano ML, Borghese F, Carlesimo M, Pimpinelli F, Fiorilli M, Casato M: Efficacy of low-dose rituximab for mixed cryoglobulinemia. Clin Immunol 125: 30-33, 2007
63. Lamprecht P, Lerin-Lozano C, Merz H, Dennin RH, Gause A, Voswinkel J, Peters SO, Gutzeit O, Arlt AC, Solbach W, Gross WL: Rituximab induces remission in refractory HCV associated cryoglobulinemic vasculitis. Ann Rheum Dis 62: 1230-1233, 2003
64. Fabrizi F, Lunghi G, Messa P, Martin P: Therapy of hepatitis C-associated glomerulonephritis: Current approaches. J Nephrol 21: 813-825, 2008
65. Korte MR, van Heerde MJ, de Man RA, Betjes MH: Rituximab for the treatment of glomerulonephritis in hepatitis C associated cryoglobulinemia. Neth J Med 66: 27-30, 2008
66. Quartuccio L, Salvin S, Fabris M, Sacco S, De Vita S: Disappearance of bone marrow B cell clonal expansion in patients with type II hepatitis C virus-related cryoglobulinemic glomerulonephritis after clinical efficient rituximab therapy. Ann Rheum Dis 67: 1494-1495, 2008
67. Quartuccio L, Soardo G, Romano G, Zaja F, Scott CA, De Marchi G, Fabris M, Ferraccioli G, De Vita S: Rituximab treatment for glomerulonephritis in HCV-associated mixed cryoglobulinemia: Efficacy and safety in the absence of steroids. Rheumatology 45: 842-846, 2006
68. Kamar N, Rostaing L, Alric L: Treatment of hepatitis Cvirus-related glomerulonephritis. Kidney Int 69: 436-439, 2006
69. Pandrangi S, Singh A, Wheeler DE, Rossi NF: Rituximab treatment for a patient with type I cryoglobulinemic glomerulonephritis. Nat Clin Pract Nephrol 4: 393-397, 2008
70. Ghijsels E, Lerut E, Vanrenterghem Y, Kuypers D: Anti-CD20 monoclonal antibody (rituximab) treatment for hepatitis C-negative therapy-resistant essential mixed cryoglobulinemia with renal and cardiac failure. Am J Kidney Dis 43: e34-e38, 2004
71. Bhat P, Weiss S, Appel GB, Radhakrishnan J: Rituximab treatment of dysproteinemias affecting the kidney: A review of three cases. Am J Kidney Dis 50: 641-644, 2007
72. Mutluay R, Aki SZ, Erten Y, Konca C, Yagci M, Barit G, Sindel S: Membranoproliferative glomerulonephritis and light-chain nephropathy in association with chronic lymphocytic leukemia. Clin Nephrol 70: 527-531, 2008
73. Bartel C, Oberma Ller N, Rummel MJ, Geiger H, Hauser IA: Remission of a B cell CLL-associated membranoproliferative glomerulonephritis type I with rituximab and bendamustine. Clin Nephrol 69: 285-289, 2008
74. Rosenstock JL, Markowitz GS, Valeri AM, Sacchi G, Appel GB, D'Agati VD: Fibrillary and immunotactoid glomerulonephritis: Distinct entities with different clinical and pathologic features. Kidney Int 63: 1450-1461, 2003
75. Collins M, Navaneethan SD, Chung M, Sloand J, Goldman B, Appel G, Rovin BH: Rituximab treatment of fibrillary glomerulonephritis. Am J Kidney Dis 52: 1158-1162, 200